The annual industry report of the Pharmapack Europe event suggests there will be significant innovation in inhaled pulmonary and intranasal drug delivery in 2024.
The annual industry report of the Pharmapack Europe event—taking place in Paris, France, between Jan. 24 and 25, 2024—has been published and suggests that there will be significant innovation in the areas of inhaled pulmonary and intranasal drug delivery over the coming 12 months.
Innovation in inhalation devices is expected to be a major shift for the industry, according to the Pharmapack report, which was created from an industry survey of 200 participants and added analysis by Pharmacentric Solutions, Springboard, and Team Consulting. Moving beyond asthma and chronic obstructive pulmonary disease (COPD), the report specifies that inhalation devices will be tailored to meet the requirements of newer alternative therapies for conditions such as lung cancer, idiopathic pulmonary fibrosis, and Parkinson’s disease. Providing an example of how the delivery devices will evolve, the report highlighted intranasal delivery of both liquid and solid therapies targeting central nervous system and systemic delivery that would have only been previously administered via injection.
Additionally, the report showed that a greater proportion of the industry is leaning towards novel auto-injector development rather than on-body devices as a result of the costs associated with the latter and the ease of use of the former. Challenges with on-body devices that were specified in the report include skin cleaning, adhesive peeling, and prolonged wearing. A particular area of interest for drug delivery devices in the coming year that was identified in the report was that of auto-injector innovation for glucagon-like peptide 1 drugs.